Stockreport

Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan

Mirum Pharmaceuticals, Inc. - common stock  (MIRM) 
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm Check Earnings Report
PDF Partnership leverages Takeda’s leadership in rare disease, gastroenterology, and hepatology to advance maralixibat in a major market FOSTER CITY, Calif. & OSAKA, Japa [Read more]